ciprofloxacin hydrochloride + dexamethasone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ciprofloxacin hydrochloride + dexamethasone: clinical details
Prescribing considerations
- Confirm acute bacterial otitis externa; corticosteroid activity may mask persistent or secondary infection.
- Safety and efficacy are established from one year of age. Use below this age requires an individual benefit–risk assessment.
- Persistent or recurrent discharge warrants assessment for an underlying condition.
- Prolonged use may select non-susceptible bacteria, yeasts or fungi.
Contraindications and cautions
- Hypersensitivity to ciprofloxacin, another quinolone, dexamethasone or an excipient
- Viral otic infection, including varicella or herpes simplex
- Fungal otic infection
Monitoring
- Clinical response and signs of superinfection
- Rash or other hypersensitivity features
- Tendon pain or inflammation, particularly in older patients or those receiving systemic corticosteroids
- Blurred vision or other visual disturbance
Clinical pharmacology
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV. Dexamethasone activates intracellular corticosteroid receptors and alters transcription of inflammatory mediators. Plasma exposure to both components is very low after topical ear administration.
Formulation and product differences
- White to off-white suspension that must be shaken before use
- Contains benzalkonium chloride, which may irritate the skin
- Protect from light, do not freeze and discard four weeks after first opening
ciprofloxacin hydrochloride + dexamethasone preparations and strengths
Ear drops
Route: Otic
Strengths: 3 mg/mL + 1 mg/mL
ciprofloxacin hydrochloride + dexamethasone interactions
Specific interaction studies have not been performed. Systemic exposure after use in the ear is low, so clinically important pharmacokinetic interactions are considered unlikely.
Warfarin and related oral anticoagulants
Systemic quinolones can increase anticoagulant effects, although a clinically important interaction is unlikely with these ear drops because ciprofloxacin exposure is low.
Cyclosporine
Temporary creatinine increases have occurred with systemic quinolones, but a clinically important interaction is unlikely after use in the ear.
Theophylline and other methylxanthines
Oral ciprofloxacin can slow their metabolism, but a clinically important effect is unlikely after use in the ear.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.